Press releaseGlobe Newswire
Belite Bio
BLTE · NASDAQ
$154.45+$7.11 (+4.83%)TodayMarket closed ·
Prev close $147.34
Latest news
- News
Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1
- Press releaseGlobe Newswire
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
- News
Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1
- Press releaseGlobe Newswire
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
- NewsVandana Singh
Why Is Belite Bio Stock Soaring Friday?
- News
Full Transcript: Belite Bio Q2 2026 Earnings Call
- Press releaseGlobe Newswire
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
- Press releaseGlobe Newswire
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
- NewsVandana Singh
Why Is Belite Bio Stock Gaining Monday?
- Press releaseGlobe Newswire
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
- Press releaseGlobe Newswire
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
- News
Full Transcript: Belite Bio Q1 2026 Earnings Call
- News
Earnings Scheduled For May 20, 2026
- News
Earnings Scheduled For March 2, 2026
- News
Exploring Belite Bio's Earnings Expectations
- NewsVandana Singh
Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease
- News
Earnings Scheduled For November 10, 2025
- News
Earnings Outlook For Belite Bio
- News
Earnings Scheduled For August 11, 2025
- News
Belite Bio's Earnings Outlook
- NewsAvi Kapoor
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday
- News
Insights into Belite Bio's Upcoming Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.